| Literature DB >> 32685485 |
Ngou In Pang1, Ruixue Bie1, Carolina Oi Lam Ung1, Hao Hu1.
Abstract
Cancer is the leading cause of morbidity and mortality, and about one in six people die from cancer globally. Approximately 20% to 70% of cancer patients are accompanied with malnutrition, and nutrition support plays an important role among cancer patients. However, the utilization of nutrition support is generally irrational in clinical practices and it is affected by multiple factors. Logic models not only present a framework to improve intervention of health care setting but also identify all the elements, pathways, outcomes, and their relationships between systems. This study developed a logic model of nutrition support for cancer patients based on current literature and conducted interview with medical staff in Macao to validate the logic model. In addition, suggestions were given as references to improve the utilization of nutrition support among cancer patients.Entities:
Mesh:
Year: 2020 PMID: 32685485 PMCID: PMC7334779 DOI: 10.1155/2020/4513719
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
PICO framework (population, intervention, comparison, and outcomes).
| PICO | |
|---|---|
| Population | Which population are the target population and its information? |
| Patients with cancer receiving nutrition support. Demographic information of cancer patients. | |
| Intervention | What kind of intervention will be performed among cancer patients? |
| Activities related to nutrition and performed among cancer patients and that caused specific outcomes. | |
| Comparison | How to conduct comparison? |
| Difference based on the actions or changes. | |
| Outcomes | Which types of outcomes will be caused? Positive or negative? |
| Changes that were caused by specific actions directly or indirectly, such as biochemical index, mortality, length of hospital stay, quality of life, and medical cost. |
Summary of study design of included literatures.
| Design | Number | Papers |
|---|---|---|
| Randomized controlled trial (RCT) | 5 | Zhao et al. (2017), Obling et al. (2017), Cereda et al. (2018), Kabata et al. (2015), Hatao et al. (2017) |
| Randomized trial (RT) | 6 | Takesue et al. (2015), Okada et al. (2017), De Luis et al. (2015), Sánchez-Lara et al. (2014), Gavazzi et al. (2016), Vidal et al. (2016) |
| Longitudinal study | 1 | Vashi et al. (2014) |
| Observational study | 1 | Brown et al. (2017) |
| Interview | 1 | Cohen et al. (2017) |
| Questionnaire | 1 | Santarpia and Bozzetti (2018) |
| Cohort study | 1 | Shenep et al. (2017) |
| Single/double/multicenter study | 1 | Senesse et al. (2015) |
| Mixed method | 13 | Wang et al. (2015), Bowrey et al. (2015), Wang et al. (2018), Yu et al. (2017), Jin et al. (2018), Ding et al. (2015), Yang et al. (2015), Li et al. (2015), Cotogni et al. (2017), Kobayashi et al. (2017), Miyata et al. (2017), Li et al. (2015), Mendivil et al. (2017) |
| Total | 30 |
Elements of included literatures.
| Elements | Contents |
|---|---|
| Demographic information | (i) Gender |
| (ii) Age | |
| Cancer types | (i) (Incurable/upper/primary/secondary) gastrointestinal cancer, esophageal cancer, esophageal cancer, rectal carcinoma, colon carcinoma, duodenal carcinoma |
| (ii) (Advanced-stage epithelial) ovarian cancer, fallopian tube and primary peritoneal cancer, pancreatic carcinoma, appendix cancer, head and neck cancer, advanced non-small-cell lung cancer, hepatic carcinoma, bladder cancer | |
| (iii) Abdominal cavity malignancy, cancer-related cachexia, pediatric oncology | |
| Disease stages | (i) Stages I–IV, advanced stage |
| Surgery | (i) Thoracic surgery |
| (ii) Elective esophagectomy, esophageal resection | |
| (iii) Total gastrectomy, radical gastrectomy | |
| (iv) Elective major gastrointestinal tract surgery, bowel resection | |
| (v) Ablative surgery, extended pelvic lymphadenectomy, radical cystectomy, cytoreductive surgery, debulking surgery | |
| Treatments | (i) Chemotherapy (systemic, neoadjuvant), hormonal therapy, paclitaxel and cisplatin/carboplatin treatment, radiotherapy (plus systemic treatment), surgical therapy |
| Participants | (i) Patient, home health nurse, caregiver, physician, family member, nutrition team, nutritionist, general practitioner, oncologist, medical, nursing and allied health staff, dietitian, psychologist, speech pathologist, radiation oncologist, and medical oncologist. |
| Nutrition types | (i) EN: enteral nutritional emulsion (TPF-T), isocaloric and isonitrogenous enteral formula, protein EN powder, home enteral nutrition (HEN), omega-3-rich EN |
| (ii) PN: home parenteral nutrition (HPN), total parenteral nutrition (TPN), supplemental home parenteral nutrition (sHPN) | |
| (iii) Other: fiber-free/enriched/and probiotic-enriched nutrition formula, low-nitrogen and low-calorie PN combined with EN | |
| Nutrition routes | (i) EN: nutrition pump, jejunostomy feeding, oral, electronic pump, peripheral intravenous infusion, nasal-intestinal tube, intraoperatively placed nasogastric tube, enteral feeding tube, oral feeding, transnasal tube |
| (ii) PN: central venous catheter, subcutaneous port, external central venous catheter, peripheral-venous route, gastrostomy tube, peripherally inserted central catheter | |
| Timing | (i) No specific |
| (ii) No more than 7 days prior to chemotherapy administration, after the first chemotherapy cycle, and after the second chemotherapy cycle, day 3 before the initiation of chemotherapy to day 12 of chemotherapy | |
| (iii) Preoperation: 1 day, 1 week | |
| (iv) Day of surgery | |
| (v) Postoperation: 24, 48, and 48-72 hours, 7 days, the day that the patient began eating a postoperative diet | |
| Duration | (i) Days: 2-14 |
| (ii) Weeks: 1-6 | |
| (iii) Months: 2-6 | |
| Health outcomes | (i) Complication rates (postoperative, jejunostomy tube) |
| (ii) Nutritional status nutritional assessment | |
| (iii) Clinical, biochemical, laboratory, and hematological parameters, blood chemistry | |
| (iv) Anthropometrics, e.g., body weight, body composition, rate of weight loss, fat free mass index, fat free mass, handgrip strength, muscle strength, six-minute walking test, protein-calorie intake, and caloric intake | |
| (v) Oncological outcomes (short-/long-term), e.g., chemotherapy-related toxicities, response to chemotherapy and survival, and anticancer treatment tolerance | |
| (vi) Functional outcomes, e.g., functional status (Karnofsky performance status (KPS)), immune function, liver function indexes, intestinal function recovery, functional capacity, bowel movement recovery, and restoration of bowel function | |
| (vii) Inflammatory markers, such as tumor necrosis factor- (TNF-) a and interleukin- (IL-) 6, immunoglobulins, CD3+, CD4+, CD8+, and natural killer cells, albumin and prealbumin, hemoglobin, inflammatory response, and duration of systematic inflammatory response syndrome | |
| (viii) Quality of life (generic and disease-specific), e.g., physical/role/emotional functioning, appetite loss, and fatigue | |
| (ix) Other, e.g., days for first fecal passage, blood glucose (BG) values, adherence to nutrition support, and phase angle | |
| Nonhealth outcomes | (i) Length of hospital stay, length of postoperative hospital stay, hospital readmission rates |
| (ii) Cost of hospitalization, cost-effectiveness, initial hospitalization cost | |
| (iii) Attitude, impact, information, support, and clinical management regarding nutrition support | |
| (iv) Experiences of living jejunostomy tube and home feeding, level of family strain, psychological status | |
| Adverse reactions | (i) Abdominal pain, vomiting/nausea, anastomotic fistula, and abdominal distension, oral mucositis, diarrhea, bloodstream infection, catheter occlusion, drug extravasation, intravascular thrombosis, bleeding, exudates, swelling, induration |
| Setting | (i) Different timing/duration (preoperation versus postoperation) |
| (ii) Different dose and intensity (rich/free fiber formula) | |
| (iii) Different nutrition types (EN versus PN) | |
| (iv) Different routes (nasoenteral feeding tube versus intravenous infusion) | |
| (v) Different care/counselling (standard care versus nutrition care) | |
| (vi) Different nutrition support versus control (EN versus placebo) |
Figure 1First version of the logic model.
Figure 2Second version of the logic model.
Barriers of nutrition support among cancer patients.
| Barriers | Possible reason |
|---|---|
| Misunderstanding of nutrition support | Many cancer patients and their families ignored the importance of nutrition support and misunderstand its effects. |
| Economic factors | Cancer therapies are long-term and costly. |
| Lack of standard guidelines | The adherence to the guidelines published by nutritional institutions needs to be improved, and the medical staff want more detailed and practical guidance. |
| Over workload | Nutrition support always accompanies with long-term nutrition counselling for cancer patients during the whole therapy program, and it takes lot of human resource. |
| Loss of appetite | Many cancer patients will lose their appetites and need regular nutrition assessment and adjustment of nutrition support. |
Suggestions for different populations.
| Population | Suggestions |
|---|---|
| Policy maker | To update nutrition product in basic medical insurance drug catalogue regularly. |
| Hospital | To provide regular trainings and consistent and useful guidance. |
| Medical staff | To refer cancer patients and their families to nutritionists before utilization of nutrition support. |
| Researchers | To consider how to transfer the research findings to clinical practice efficiently. |